PharmaEssentia Corporation (LUX:261280523)

PharmaEssentia Statistics

Total Valuation

PharmaEssentia has a market cap or net worth of EUR 7.02 billion. The enterprise value is 6.43 billion.

Market Cap	7.02B
Enterprise Value	6.43B

Important Dates

The last earnings date was Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	Aug 11, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.14%
Shares Change (QoQ)	+0.29%
Owned by Insiders (%)	8.16%
Owned by Institutions (%)	8.74%
Float	295.53M

Valuation Ratios

The trailing PE ratio is 51.34 and the forward PE ratio is 32.22.

PE Ratio	51.34
Forward PE	32.22
PS Ratio	16.57
PB Ratio	8.10
P/TBV Ratio	8.16
P/FCF Ratio	76.93
P/OCF Ratio	49.07
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 44.97, with an EV/FCF ratio of 70.45.

EV / Earnings	47.01
EV / Sales	15.17
EV / EBITDA	44.97
EV / EBIT	48.18
EV / FCF	70.45

Financial Position

The company has a current ratio of 6.20, with a Debt / Equity ratio of 0.03.

Current Ratio	6.20
Quick Ratio	5.84
Debt / Equity	0.03
Debt / EBITDA	0.16
Debt / FCF	0.25
Interest Coverage	193.04

Financial Efficiency

Return on equity (ROE) is 16.97% and return on invested capital (ROIC) is 51.42%.

Return on Equity (ROE)	16.97%
Return on Assets (ROA)	9.00%
Return on Invested Capital (ROIC)	51.42%
Return on Capital Employed (ROCE)	15.06%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	3.24M
Profits Per Employee	1.04M
Employee Count	131
Asset Turnover	0.46
Inventory Turnover	1.29

Taxes

Income Tax	-1.69M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.92% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+11.92%
50-Day Moving Average	19.16
200-Day Moving Average	17.54
Relative Strength Index (RSI)	50.81
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaEssentia had revenue of EUR 424.05 million and earned 136.84 million in profits. Earnings per share was 0.37.

Revenue	424.05M
Gross Profit	378.37M
Operating Income	133.67M
Pretax Income	135.15M
Net Income	136.84M
EBITDA	137.28M
EBIT	133.67M
Earnings Per Share (EPS)	0.37

Balance Sheet

The company has 615.50 million in cash and 23.22 million in debt, with a net cash position of 592.28 million.

Cash & Cash Equivalents	615.50M
Total Debt	23.22M
Net Cash	592.28M
Net Cash Per Share	n/a
Equity (Book Value)	867.25M
Book Value Per Share	2.34
Working Capital	660.79M

Cash Flow

In the last 12 months, operating cash flow was 143.14 million and capital expenditures -51.84 million, giving a free cash flow of 91.31 million.

Operating Cash Flow	143.14M
Capital Expenditures	-51.84M
Free Cash Flow	91.31M
FCF Per Share	n/a

Margins

Gross margin is 89.23%, with operating and profit margins of 31.52% and 32.27%.

Gross Margin	89.23%
Operating Margin	31.52%
Pretax Margin	31.87%
Profit Margin	32.27%
EBITDA Margin	32.37%
EBIT Margin	31.52%
FCF Margin	21.53%

Dividends & Yields

This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 0.09%.

Dividend Per Share	0.02
Dividend Yield	0.09%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	7.26%
Buyback Yield	-0.14%
Shareholder Yield	-0.05%
Earnings Yield	1.95%
FCF Yield	1.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaEssentia has an Altman Z-Score of 22.46 and a Piotroski F-Score of 7.

Altman Z-Score	22.46
Piotroski F-Score	7